Teva and Immunai partner to improve clinical decision making
The companies will focus on mechanisms of action, dose selection and biomarker analyses
Read Moreby Emily Kimber | Nov 18, 2024 | News | 0
The companies will focus on mechanisms of action, dose selection and biomarker analyses
Read Moreby Emily Kimber | Sep 18, 2024 | News | 0
It is hoped that the tool will improve the diagnostic pathway and free up radiologists’ time
Read Moreby Jen Brogan | Aug 16, 2024 | News | 0
This form of cancer was responsible for 1.9 million diagnosed cases worldwide in 2020
Read Moreby Jen Brogan | Aug 14, 2024 | News | 0
Heart failure with preserved ejection fraction makes up 50% of all UK heart failure cases
Read Moreby Jen Brogan | Aug 9, 2024 | News | 0
In the UK, there are an estimated 11 million people living with a neurological condition
Read Moreby Jen Brogan | Aug 8, 2024 | News | 0
The study predicted the development of conditions including Alzheimer’s and heart disease
Read Moreby Jen Brogan | Jul 18, 2024 | News | 0
The most commonly diagnosed cancer in men in the UK leads to over 12,000 annual deaths
Read Moreby Jen Brogan | Jul 10, 2024 | News | 0
Around one in five dementia hospitalisations are due to potentially preventable causes
Read Moreby Jen Brogan | Jun 17, 2024 | News | 0
Cancer was estimated to be responsible for more than 18 million cases worldwide in 2020
Read Moreby Jen Brogan | Jun 17, 2024 | News | 0
Medulloblastoma is responsible for around 52 new cases in children in the UK every year
Read Moreby Jen Brogan | Jun 11, 2024 | News | 0
The leading cause of cancer globally accounts for an estimated 1.8 million deaths annually
Read Moreby Jen Brogan | May 10, 2024 | News | 0
The sandbox will help to inform future AI Airlock projects and influence future AlaMD guidance
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479